Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Multimodal Assessment of Neuromuscular Electrical Stimulation (NMES) Effects on Respiratory and Peripheral Muscles in Chronic Obstructive Pulmonary Disease (COPD) (NMES in COPD)

11. November 2026 aktualisiert von: Universitas Padjadjaran

Comparative Effects of Targeted Neuromuscular Electrical Stimulation (NMES) on Respiratory and Peripheral Muscles in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Multimodal Assesment Using Diaphragm Ultrasound and Plasma Biomarkers (Interleukin-6 and Insulin-like Growth Factor- 1)

The goal of this clinical trial is to learn if targeted neuromuscular electrical stimulation (NMES) can treat respiratory and peripheral muscle weakness in patients with chronic obstructive pulmonary disease (COPD). The main questions it aims to answer are:

  • Does targeted NMES improve diaphragm thickening fraction and excursion as measured by diaphragm ultrasound?
  • What are the comparative effects of targeted NMES on plasma biomarkers, specifically Interleukin-6 (IL-6) and Insulin-like Growth Factor-1 (IGF-1)? Researchers will compare three groups: the first intervention group receiving intercostal NMES combined with Pursed-Lip Breathing (PLB), the second intervention group receiving quadriceps NMES combined with PLB, and a control group receiving sham upper trapezius NMES combined with PLB, to see if targeted NMES provides superior improvements in respiratory and peripheral muscle function.

Participants will:

  • Undergo baseline screening, including a diaphragm ultrasound and a blood draw for plasma biomarkers (IL-6 and IGF-1)
  • Be randomly assigned to one of the three groups to receive either intercostal NMES, quadriceps NMES, or sham upper trapezius NMES, all combined with Pursed-Lip Breathing exercises
  • Complete a post-intervention assessment involving repeat ultrasound imaging and biomarker analysis to evaluate muscle and systemic changes

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Chronic Obstructive Pulmonary Disease (COPD) is characterized by chronic airflow limitation and progressive respiratory and peripheral muscle dysfunction. While pulmonary rehabilitation is a cornerstone of management, severe breathlessness often limits a patient's exercise tolerance. Neuromuscular Electrical Stimulation (NMES) offers an alternative modality to train specific muscle groups without inducing severe dyspnea. However, the comparative efficacy of stimulating respiratory muscles versus peripheral muscle groups requires deeper investigation using precise physiological and biochemical markers.

This study utilizes a three-arm randomized controlled design to evaluate and compare the localized and systemic effects of targeted NMES. The mechanical properties of the respiratory system will be monitored using diaphragm ultrasound, focusing on active contractility and movement. Concurrently, systemic inflammation and muscle anabolic responses will be analyzed through plasma biomarkers to understand the underlying biomolecular pathways.

Upon meeting the eligibility criteria and providing written informed consent, the 45 participants will be randomly assigned to one of three study arms in a 1:1:1 ratio. All participants will undergo a standardized baseline assessment. Following the allocation, each group will complete their designated 8-week intervention protocol consisting of 3 sessions per week (total of 24 sessions) concurrently with Pursed-Lip Breathing (PLB) training. A comprehensive post-intervention reassessment will be conducted immediately following the final session to determine the comparative physiological and biochemical outcomes.

Studientyp

Interventionell

Einschreibung (Geschätzt)

45

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • West Java
      • Bandung, West Java, Indonesien
        • Rekrutierung
        • Faculty of Medicine Universitas Padjadjaran

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

40 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Patients diagnosed with stable Chronic Obstructive Pulmonary Disease (COPD), GOLD spirometric grade 2-4 (post-bronchodilator FEV1/FVC <0.70 with FEV1 <80% predicted), confirmed by a pulmonologist.
  • Age ≥ 40 years old.
  • Willing to participate in the study and sign the written informed consent form.

Exclusion Criteria:

  • Recent thoracic or abdominal surgery, pneumothorax, or a history of spontaneous pneumothorax.
  • Participation in other structured respiratory muscle training or pulmonary rehabilitation programs that may confound the study results.
  • Presence of neuromuscular, bulbar, laryngeal, or other disorders that may independently impair respiratory muscle function.
  • Use of a cardiac pacemaker or any metal/electronic implant at the intended stimulation area.
  • Diagnosis of heart failure classified as NYHA (New York Heart Association) class III-IV.
  • Presence of skin lesions, open wounds, or active dermatitis in the intended electrode placement areas.
  • Current use of systemic (oral) corticosteroids or history of use within 4 weeks prior to enrollment.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Intercostal NMES + PLB

Participants receive targeted NMES to the intercostal muscles combined with Pursed-Lip Breathing (PLB) exercises. The protocol is administered 3 times per week for 8 weeks.

Intercostal Neuromuscular Electrical Stimulation (NMES) is a procedure that uses small electrical impulses delivered through electrodes on the skin to stimulate motor nerves and cause passive muscle contractions which will be applied to the intercostal muscles

Pursed-lip breathing is a simple respiratory exercise that involves inhaling slowly through your nose and exhaling gently through tightly puckered or "pursed" lips (as if whistling or blowing out a candle).

Experimental: Quadriceps NMES + PLB

Participants receive targeted NMES to the quadriceps muscles combined with Pursed-Lip Breathing (PLB) exercises. The protocol is administered 3 times per week for 8 weeks.

Pursed-lip breathing is a simple respiratory exercise that involves inhaling slowly through your nose and exhaling gently through tightly puckered or "pursed" lips (as if whistling or blowing out a candle).

Quadriceps Neuromuscular Electrical Stimulation (NMES) is a procedure that uses small electrical impulses delivered through electrodes on the skin to stimulate motor nerves and cause passive muscle contractions which will be applied to the quadriceps muscles

Placebo-Komparator: Sham NMES + PLB

Participants receive sham NMES to the upper trapezius muscles combined with Pursed-Lip Breathing (PLB) exercises. The protocol is administered 3 times per week for 8 weeks.

Pursed-lip breathing is a simple respiratory exercise that involves inhaling slowly through your nose and exhaling gently through tightly puckered or "pursed" lips (as if whistling or blowing out a candle).

Sham Neuromuscular Electrical Stimulation (NMES) is a control procedure that delivers minimal electrical impulses via transcutaneous skin patches to the upper trapezius muscles, generating only a mild tingling sensation as a placebo effect without triggering any passive muscle contractions.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Diaphragm Excursion (DE)
Zeitfenster: Baseline (Week 0) and post-intervention (Week 8)

Measured via B-mode or M-mode transabdominal ultrasound during quiet and deep breathing to evaluate the distance the diaphragm travels vertically. A higher excursion value indicates better diaphragmatic mobility.

Baseline (Week 0) and post-intervention (Week 8)
Diaphragm Thickening Fraction (TF)
Zeitfenster: Baseline (Week 0) and post-intervention (Week 8)

Calculated using the formula: [(Thickness at end-inspiration - Thickness at end-expiration) / Thickness at end-expiration] x 100%. Measured via high-frequency linear ultrasound at the zone of apposition to assess diaphragmatic contractile function.

Baseline (Week 0) and post-intervention (Week 8)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Plasma Interleukin-6 (IL-6) Levels
Zeitfenster: Baseline (Week 0) and post-intervention (Week 8)

Measured via Enzyme-Linked Immunosorbent Assay (ELISA) from venous blood samples to evaluate systemic inflammatory profiles. Decreased levels indicate a reduction in systemic inflammation.

Baseline (Week 0) and post-intervention (Week 8)
Change in Plasma Insulin-like Growth Factor-1 (IGF-1) Levels
Zeitfenster: Baseline (Week 0) and post-intervention (Week 8)

Measured via Enzyme-Linked Immunosorbent Assay (ELISA) from venous blood samples to evaluate muscle anabolic activity and systemic growth factor response. Increased levels indicate an improved anabolic state.

Baseline (Week 0) and post-intervention (Week 8)

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Six-Minute Walk Test (6MWT) Distance
Zeitfenster: Baseline (Week 0) and post-intervention (Week 8)

Measured by the total distance in meters that a participant can walk quickly on a flat, hard surface in a period of 6 minutes. It evaluates functional exercise capacity.

Baseline (Week 0) and post-intervention (Week 8)
Modified Medical Research Council (mMRC) Dyspnea Scale
Zeitfenster: Baseline (Week 0) and post-intervention (Week 8)

A questionnaire used to rate the baseline dyspnea (breathlessness) on a scale from 0 (breathless only with strenuous exercise) to 4 (too breathless to leave the house). Lower scores indicate less respiratory disability.

Baseline (Week 0) and post-intervention (Week 8)
COPD Assessment Test (CAT) Score
Zeitfenster: Baseline (Week 0) and post-intervention (Week 8)

An 8-item questionnaire measuring the health status impairment in COPD patients. Scores range from 0 to 40, where higher scores signify a worse health status and severe impact of COPD on the patient's life.

Baseline (Week 0) and post-intervention (Week 8)
Modified Borg Scale (MBS) for Dyspnea
Zeitfenster: Baseline (Week 0) and post-intervention (Week 8)

A categorical scale ranging from 0 (no breathlessness at all) to 10 (maximal breathlessness) used to assess the patient's perceived level of shortness of breath during functional activity or rest.

Baseline (Week 0) and post-intervention (Week 8)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. November 2026

Primärer Abschluss (Geschätzt)

1. Oktober 2027

Studienabschluss (Geschätzt)

1. März 2028

Studienanmeldedaten

Zuerst eingereicht

26. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

26. Oktober 2026

Zuerst gepostet (Tatsächlich)

2. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • IKFR-202609.01
  • 004/PEG-PRJ/SL/UKM/X/2026 (Andere Zuschuss-/Finanzierungsnummer: Maranatha Christian University)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data will not be made publicly available to protect participant privacy

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .